Article 08 Mar 2024 What's Next For Drug Importation? Potential Next Steps After FDA Authorizes Florida's Section 804 Importation Program Worldwide Healthcare
Article 30 Jan 2024 U.S. Life Sciences Regulatory And Compliance Outlook 2024 (Part II): Product Development And Pricing (Podcast) United States Healthcare
Article 20 Dec 2023 Biden Administration's Proposal Under Bayh-Dole Act Signals Enhanced Focus On Use Of March-In Rights And Lower Drug Pricing United States Healthcare
Article 12 Jul 2023 Continued Agency Strides Towards IRA Negotiation Program Implementation: CMS Issues Final Guidance On The 2026 Inflation Reduction Act Medicare Part D Negotiation Process United States Healthcare
Article 26 Jun 2023 A New Wave Of Agency Action Around Drug Pricing: CMS Proposes Sweeping Medicaid Drug Rebate Program Rule United States Healthcare
Article 20 Jan 2022 CMS Proposes Revised Definition Of Medicare Part D Drug "Negotiated Prices": Rule Could Increase Predictability For Pharmacies And Lower Medicare Enrollee Drug Cost-Sharing But Increase Premiums United States Healthcare
Article 16 Dec 2021 A New Year For Drug Pricing And Price Reporting? What's Happening Now And What's New For 2022 United States Healthcare
Article 08 Feb 2021 2022 Medicare Advantage And Part D Final Rule Includes Update To Star Ratings System And Implementing Coverage And Transparency Measures United States Healthcare
Article 14 Jan 2021 Rutledge vs. PCMA: SCOTUS Greenlights State Regulation Of Pharmacy Benefit Manager Drug Reimbursement United States Employment
Article 28 Dec 2020 Midnight Changes To The Medicaid Drug Rebate Program Regulations United States Healthcare